Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients - North Carolina, 2009

Journal of Infectious Diseases

Volumn 203, Issue 6, 2011, Pages 838-846

  Chen, Luke F ^a   Dailey, Natalie J M ^b,c   Rao, Agam K ^c,d   Fleischauer, Aaron T ^b,c   Greenwald, Ian ^a   Deyde, Varough M ^c   Moore, Zack S ^b   Anderson, Deverick J ^a   Duffy, Jonathan ^c,d   Gubareva, Larisa V ^c   Sexton, Daniel J ^a   Fry, Alicia M ^c   Srinivasan, Arjun ^d   Wolfe, Cameron R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; HISTIDINE; INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; SIALIDASE; TYROSINE; ZANAMIVIR;

2009 H1N1 INFLUENZA; ADULT; AGED; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DRUG DOSE INCREASE; EPIDEMIC; FEMALE; HEALTH CARE PERSONNEL; HEALTH VISITOR; HOSPITAL INFECTION; HUMAN; IC 50; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SYMPTOMATOLOGY; UNITED STATES; VIRUS ISOLATION;

ADULT; AGED; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CROSS INFECTION; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; HOSPITALS; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INTERVIEWS AS TOPIC; MIDDLE AGED; NORTH CAROLINA; OSELTAMIVIR; PANDEMICS; PHYLOGENY; RETROSPECTIVE STUDIES;

EID: 79952328206     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq124     Document Type: Article

References (23)

1. Centers for Disease Control Prevention. Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009; 58:400-2.
2. FluView - A weekly influenza surveillance report prepared by the influenza Division. http://www.cdc.gov/flu/weekly/. Accessed 23 October 2010.
3. Le QM, Wertheim HF, Tran ND, van Doorn HR, Nguyen TH, Horby P. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 2009; 362:86-7.
4. Centers for Disease Control Prevention. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:969-72.
5. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001; 183:523-31. (Pubitemid 32147507)
6. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605-15.
7. Deyde VM, Sheu TG, Trujillo AA, et al. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother 2010; 54:1102-10.
8. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325:197-201.
9. World Health Organization. Sequencing primers and protocol, http://www.who.int/csr/resources/publications/swineflu/sequencing--primers/en/ index.html. Accessed 22 October 2010.
10. Deyde V, Garten R, Sheu T, et al. Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006-2008. Influenza Other Respi Viruses 2009; 3:297-314.
11. Zwickl DJ. Genetic algorithm approaches for the phylogenetic analysis of large biological sequence datasets under the maximum likelihood criterion. Austin, TX: The University of Texas, 2006. Ph.D. dissertation.
12. Page R. D. M. TREEVIEW: An application to display phylogenetic trees on personal computers. Computer Applications in the Biosciences 1996; 12:357-358.
13. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52:3284-92.
14. Centers for Disease Control Prevention. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:893-6.
15. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 460:1021-5.
16. Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009; 361:2296-7.
17. Ciblak MA, Albayrak N, Odabas Y, et al. Cases of influenza A(H1N1)v reported in Turkey, May-July 2009. Euro Surveill 2009; 14:pii:19304.
18. Yang J, Yang F, Huang F, Wang J, Jin Q. Subclinical infection with the novel Influenza A (H1N1) virus. Clin Infect Dis 2009; 49:1622-3.
19. Redelman-Sidi G, Sepkowitz KA, Huang CK, et al. 2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. J Infect 2010; 60:257-63.
20. Centers for Disease Control, Prevention. Treatment (Antiviral drugs). http://www.cdc.gov/flu/professionals/antivirals/. Accessed 23 October 2010.
21. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189:440-9. (Pubitemid 38210580)
22. Daniels TL, Talbot TR. Unmasking the confusion of respiratory protection to prevent influenza-like illness in crowded community settings. J Infect Dis 2010; 201:483-5.
23. Centers for Disease Control and Prevention. Prevention strategies for seasonal influenza in healthcare settings. http://www.cdc.gov/flu/professionals/ infectioncontrol/healthcaresettings.htm. Accessed 23 October 2010.